Browse studies, page 716
Page 716 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- 1152-P: Effect of Initiating Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists on Health-Care Costs among Patients with Type 2 Diabetes Diabetes, 2020
- Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting PharmacoEconomics - Open, 2022
- To Compare The Effects Of Empagliflozin And Metformin On Serum Vitamin D Levels In Patients With Metabolic Syndrome Pakistan journal of medicine and dentistry, 2026
- Real-world safety and effectiveness of empagliflozin (Diampa®) alone or in combination with metformin (Diampa-M®) in patients with type 2 diabetes mellitus in Pakistan: a multicenter observational study BMC Endocrine Disorders, 2026
- Comparative Study of Different Derivative Spectrophotometric Techniques for the Analysis and Separation of Metformin, Empagliflozin, and Glimepiride 2020
- Comparative Analysis of Sitagliptan vs Empagliflozin as an add on Therapy to Metformin in Pakistani Type 2 Diabetic Patients Pakistan Journal of Medical & Health Sciences, 2021
- SGLT2 Inhibitors and Their Effect on Urolithiasis: Current Evidence and Future Directions Journal of clinical medicine, 2024
- Comparative efficacy of sodium-glucose transporter 2 inhibitors on lipid profiles in nonalcoholic fatty liver disease (NAFLD): a comprehensive Bayesian network meta-analysis Annals of medicine and surgery (2012), 2025
- A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico Endocrinology, diabetes & metabolism, 2026
- Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights Healthcare (Basel, Switzerland), 2025
- Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: a phase 3 PRO-1 trial Diabetology & metabolic syndrome, 2026
- Pillar Risk-Based Treatment for Chronic Kidney Disease in People With Type 2 Diabetes: A Narrative Review Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025
- The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications Cardiovascular diabetology, 2025
- Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review Annals of medicine and surgery (2012), 2025
- Finerenone as an add-on treatment to conventional therapies for the patients with diabetic kidney disease BMC nephrology, 2026
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 Diabetes care, 2026
- Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens Clinics and practice, 2026
- Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets Biomedicines, 2025
- Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word BMC cardiovascular disorders, 2026
- Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years Alzheimer's & dementia (New York, N. Y.), 2025
- Effects of canagliflozin on kidney resistive index and oxygenation in patients with type 2 diabetes: findings obtained with ultrasonography and blood oxygenation level-dependent MRI Frontiers in clinical diabetes and healthcare, 2026
- Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders Journal of neurology, neurosurgery, and psychiatry, 2025
- Beyond the Cardio-Renal-Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins Journal of clinical medicine, 2025
- Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Cureus, 2025
- Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies International journal of hepatology, 2025
- Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention Journal of clinical medicine, 2026
- Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes Saudi medical journal, 2025
- Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025
- Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management International journal of molecular sciences, 2025
- Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024 Acta psychiatrica Scandinavica, 2026
- Current treatment for diabetes: a holistic approach Hormones (Athens, Greece), 2026
- Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications Pharmaceutics, 2025
- Effects of Combination Treatment on Renal Endothelial Function in Type 2 Diabetes Mellitus Kidney international reports, 2025
- Comparative evaluation of subgingivally‐delivered 1% metformin and Aloe vera gel in the treatment of intrabony defects in chronic periodontitis patients: A randomized, controlled clinical trial Journal of Investigative and Clinical Dentistry, 2018
- Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024) Journal of Clinical Oncology, 2025
- Effectiveness of carbohydrate counting and Dietary Approach to Stop Hypertension dietary intervention on managing Gestational Diabetes Mellitus among pregnant women who used metformin: A randomized controlled clinical trial Clinical Nutrition, 2021
- Expression of concern: “Comparison of myo‐inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial” Clinical Endocrinology, 2023
- Comparison of Metformin and Myoinositol on Clinical, Hormonal and Metabolic Profile of Patients with Polycystic Ovarian Syndrome: An Open-label Randomised Clinical Trial Journal of Clinical and Diagnostic Research, 2024
- Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride Quality of Life Research, 2015
- Options for empagliflozin in combination therapy in type 2 diabetes mellitus International Journal of General Medicine, 2016
- Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data Pharmaceutical Medicine, 2019
- Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus Journal of Gandhara Medical and Dental Science, 2022
- Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting Diabetes Therapy, 2021
- Effect of Empagliflozin On Liver Enzymes of Patients In Non-Alcoholic Steatohepatitis In Type 2 Diabetes Mellitus Journal of Gandhara Medical and Dental Science, 2023
- Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives? 2016
- 1292-P: Projected Long-Term Clinical Benefit and Cost-Effectiveness of Empagliflozin Compared with Glimepiride in Patients with Type 2 Diabetes in China Diabetes, 2019
- Efficacy and Safety of Once-Weekly Semaglutide versus Tirzepatide in Type 2 Diabetes: A 24-Week Randomized Clinical Trial Journal of Health, Wellness and Community Research, 2025
- A Comparison of Renal Effects between Empagliflozin and Linagliptin in Diabetic Patients with Chronic Kidney Disease: A Randomized Clinical Trial Iranian journal of diabetes and obesity, 2024
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers International journal of clinical pharmacology and therapeutics, 2013
- Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study Upsala journal of medical sciences, 2019
- Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus Diabetes, obesity & metabolism, 2015
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease Journal of diabetes investigation, 2019
- Hemoglobin A1c Threshold for Reduction in Bone Turnover in Men With Type 2 Diabetes Mellitus Frontiers in endocrinology, 2021
- Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies BMJ open, 2022
- Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study Nature medicine, 2022
- Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus Obesity (Silver Spring, Md.), 2020
- Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study eLife, 2023
- Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial Drugs, 2020
- Exogenous ketosis in patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control Endocrinology, diabetes & metabolism, 2021
- Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes The Journal of clinical endocrinology and metabolism, 2021
- Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus PloS one, 2023
- Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study The lancet. Diabetes & endocrinology, 2022
- Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial Diabetes care, 2021
- Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial Trials, 2020
- Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024
- Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial RMD open, 2022
- Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension Medical science monitor : international medical journal of experimental and clinical research, 2020
- An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria Cardiovascular diabetology, 2023
- Effectiveness of a Digitally Delivered Continuous Care Intervention (Defeat Diabetes) on Type 2 Diabetes Outcomes: A 12-Month Single-Arm, Pre-Post Intervention Study Nutrients, 2023
- Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus Diabetes & vascular disease research, 2021
- Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results Kidney360, 2024
- Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial BMJ open diabetes research & care, 2023
- Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus Frontiers in endocrinology, 2025
- Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study) BMC nephrology, 2023
- Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial Journal of diabetes, 2024
- Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis World journal of experimental medicine, 2024
- Progressive Weight Loss-Induced Remission of Insulin Resistance/Hyperinsulinemia and Improvements in Cardiovascular Risk Factors Diabetes, metabolic syndrome and obesity : targets and therapy, 2025
- Effect of heat therapy compared with strength training on metabolic profile, heat shock response, inflammation, cardiovascular responses and microbiota in individuals with type 2 diabetes: study protocol of a randomized trial Sao Paulo medical journal = Revista paulista de medicina, 2025
- Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374) ESMO open, 2025
- Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial The Lancet Healthy Longevity, 2025
- Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes Journal of Diabetes Research, 2021
- Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin Drugs in Context, 2015
- Starting triple oral hypoglycemic agent therapy in poorly controlled type 2 diabetes is a suitable therapeutic strategy to lower HbA1c when insulin therapy is not desired 2021
- Empagliflozin MAY attenuate adipose tissue inflammation and arterial stiffness in normotensive type 2 diabetics Journal of Hypertension, 2018
- A long-term cost-effectiveness analysis of treatments for type 2 diabetes in portugal: once-weekly semaglutide 1 MG versus once-daily empagliflozin 25 MG Revista Portuguesa de Endocrinologia Diabetes e Metabolismo, 2021
- 400-P: More Pronounced Effect of Empagliflozin-Losartan Combination Therapy on Measured GFR and Blood Pressure vs. Either of the Drugs: A Crossover RCT in People with Type 2 Diabetes Diabetes, 2022
- 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus Clinical Pharmacology : Advances and Applications, 2018
- Angiotensin profiles in patients with hypertension and type 2 diabetes with combination therapy of empagliflozin and linagliptin versus metformin and insulin glargine Journal of Hypertension, 2022
- Is Basal Nitric Oxide Activity of the Renal Vasculature Altered? Analysis of a Randomized Controlled Trial Comparing Two Combination Therapies Journal of Hypertension, 2021
- Ameliorating Metabolic Profiles After Kidney Transplantation: A Protocol for an Open-Label, Prospective, Randomized, 3-Arm, Controlled Trial Frontiers in Medicine, 2021
- Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk Scientific reports, 2025
- Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes The Journal of clinical endocrinology and metabolism, 2022
- Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers Clinical and translational science, 2023
- Impact of diabetes duration on left ventricular mass regression with empagliflozin ESC heart failure, 2023
- Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial Cardiovascular diabetology, 2025
- Effects of sodium-glucose cotransporter-2 inhibitor on atrial high-rate episodes in patients with cardiovascular implantable electronic device: a randomized controlled trial Scientific reports, 2024
- A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) Journal of diabetes research, 2024
- Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial Advances in therapy, 2025
- Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial European heart journal, 2026
- Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025
